Video

SAN ANTONIO –The San Antonio Breast Cancer Symposium had a lot to offer clinicians. Cleveland Clinic breast cancer experts Dr. Jame Abraham, Dr. Holly Pederson, and Dr. Alberto Montero outline take-home messages from research presented at the San Antonio Breast Cancer Symposium. The panel agreed that some findings were practice-changing – particularly results showing adjuvant denosumab not only reduces fracture risk for women but also improves breast cancer outcomes – while findings for other treatments, including immunotherapy for breast cancer, have a long way to go before arriving in the clinic.

Dr. Pederson highlighted presentations on prevention, including findings linking aspirin with lower breast density. She also said presentations confirmed for her that gene panels are here to stay in helping identify and manage women at high risk of breast cancer.

The panelists also discussed the clinical relevance of studies on neoadjuvant carboplatin and on using capecitabine for cleanup of residual disease after neoadjuvant therapy.

The three panelists had no financial disclosures related to these studies.

[email protected]

SAN ANTONIO –The San Antonio Breast Cancer Symposium had a lot to offer clinicians. Cleveland Clinic breast cancer experts Dr. Jame Abraham, Dr. Holly Pederson, and Dr. Alberto Montero outline take-home messages from research presented at the San Antonio Breast Cancer Symposium. The panel agreed that some findings were practice-changing – particularly results showing adjuvant denosumab not only reduces fracture risk for women but also improves breast cancer outcomes – while findings for other treatments, including immunotherapy for breast cancer, have a long way to go before arriving in the clinic.

Dr. Pederson highlighted presentations on prevention, including findings linking aspirin with lower breast density. She also said presentations confirmed for her that gene panels are here to stay in helping identify and manage women at high risk of breast cancer.

The panelists also discussed the clinical relevance of studies on neoadjuvant carboplatin and on using capecitabine for cleanup of residual disease after neoadjuvant therapy.

The three panelists had no financial disclosures related to these studies.

[email protected]

SAN ANTONIO –The San Antonio Breast Cancer Symposium had a lot to offer clinicians. Cleveland Clinic breast cancer experts Dr. Jame Abraham, Dr. Holly Pederson, and Dr. Alberto Montero outline take-home messages from research presented at the San Antonio Breast Cancer Symposium. The panel agreed that some findings were practice-changing – particularly results showing adjuvant denosumab not only reduces fracture risk for women but also improves breast cancer outcomes – while findings for other treatments, including immunotherapy for breast cancer, have a long way to go before arriving in the clinic.

Dr. Pederson highlighted presentations on prevention, including findings linking aspirin with lower breast density. She also said presentations confirmed for her that gene panels are here to stay in helping identify and manage women at high risk of breast cancer.

The panelists also discussed the clinical relevance of studies on neoadjuvant carboplatin and on using capecitabine for cleanup of residual disease after neoadjuvant therapy.

The three panelists had no financial disclosures related to these studies.

[email protected]

SAN ANTONIO – Compared with a treatment of the physician’s choice, the antibody-drug conjugate trastuzumab emtansine (T-DM1) prolongs median overall survival by almost 7 months among women with heavily pretreated HER2-positive metastatic breast cancer, according to new data from the TH3RESA trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Hans Wildiers, professor at Katholieke Universiteit Leuven, Belgium, discusses the findings and how they further solidify the role of T-DM1 in the treatment of advanced HER2-positive disease.

SAN ANTONIO – Compared with a treatment of the physician’s choice, the antibody-drug conjugate trastuzumab emtansine (T-DM1) prolongs median overall survival by almost 7 months among women with heavily pretreated HER2-positive metastatic breast cancer, according to new data from the TH3RESA trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Hans Wildiers, professor at Katholieke Universiteit Leuven, Belgium, discusses the findings and how they further solidify the role of T-DM1 in the treatment of advanced HER2-positive disease.

SAN ANTONIO – Compared with a treatment of the physician’s choice, the antibody-drug conjugate trastuzumab emtansine (T-DM1) prolongs median overall survival by almost 7 months among women with heavily pretreated HER2-positive metastatic breast cancer, according to new data from the TH3RESA trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Hans Wildiers, professor at Katholieke Universiteit Leuven, Belgium, discusses the findings and how they further solidify the role of T-DM1 in the treatment of advanced HER2-positive disease.

SAN ANTONIO – A highlight of this year’s San Antonio Breast Cancer Symposium was presentation of two large phase III trials comparing anastrozole to tamoxifen for prevention of recurrent disease in women with ductal carcinoma in situ.

In an interview, Dr. Patricia A. Ganz of the University of California, Los Angeles, breaks down the efficacy and quality of life differences between the two secondary prevention agents studied in NSABP B-35 and IBIS-II-DCIS.

[email protected]

SAN ANTONIO – A highlight of this year’s San Antonio Breast Cancer Symposium was presentation of two large phase III trials comparing anastrozole to tamoxifen for prevention of recurrent disease in women with ductal carcinoma in situ.

In an interview, Dr. Patricia A. Ganz of the University of California, Los Angeles, breaks down the efficacy and quality of life differences between the two secondary prevention agents studied in NSABP B-35 and IBIS-II-DCIS.

[email protected]

SAN ANTONIO – A highlight of this year’s San Antonio Breast Cancer Symposium was presentation of two large phase III trials comparing anastrozole to tamoxifen for prevention of recurrent disease in women with ductal carcinoma in situ.

In an interview, Dr. Patricia A. Ganz of the University of California, Los Angeles, breaks down the efficacy and quality of life differences between the two secondary prevention agents studied in NSABP B-35 and IBIS-II-DCIS.

[email protected]

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

[email protected]

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

[email protected]

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

[email protected]

SAN ANTONIO – Prophylactic beta-blockade with bisoprolol during adjuvant trastuzumab therapy for HER2-positive breast cancer prevented trastuzumab-induced decline in left ventricular ejection fraction in a randomized trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Edie Pituskin of the University of Alberta, Edmonton, explained why the double-blind, placebo-controlled MANTICORE trial may change clinical practice.

[email protected]

SAN ANTONIO – Prophylactic beta-blockade with bisoprolol during adjuvant trastuzumab therapy for HER2-positive breast cancer prevented trastuzumab-induced decline in left ventricular ejection fraction in a randomized trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Edie Pituskin of the University of Alberta, Edmonton, explained why the double-blind, placebo-controlled MANTICORE trial may change clinical practice.

[email protected]

SAN ANTONIO – Prophylactic beta-blockade with bisoprolol during adjuvant trastuzumab therapy for HER2-positive breast cancer prevented trastuzumab-induced decline in left ventricular ejection fraction in a randomized trial.

In an interview at the San Antonio Breast Cancer Symposium, Dr. Edie Pituskin of the University of Alberta, Edmonton, explained why the double-blind, placebo-controlled MANTICORE trial may change clinical practice.

[email protected]

SAN ANTONIO – Mutations of the estrogen receptor 1 (ESR1) gene are more common than previously thought in women with advanced estrogen receptor–positive breast cancer and are associated with poorer survival. In an interview at the San Antonio Breast Cancer Symposium, Dr. Sarat Chandarlapaty of Memorial Sloan Kettering Cancer Center, New York, discusses a mutational analysis of cell-free DNA in blood samples from the BOLERO-2 trial and how the findings may help refine therapeutic strategies.

SAN ANTONIO – Mutations of the estrogen receptor 1 (ESR1) gene are more common than previously thought in women with advanced estrogen receptor–positive breast cancer and are associated with poorer survival. In an interview at the San Antonio Breast Cancer Symposium, Dr. Sarat Chandarlapaty of Memorial Sloan Kettering Cancer Center, New York, discusses a mutational analysis of cell-free DNA in blood samples from the BOLERO-2 trial and how the findings may help refine therapeutic strategies.

SAN ANTONIO – Mutations of the estrogen receptor 1 (ESR1) gene are more common than previously thought in women with advanced estrogen receptor–positive breast cancer and are associated with poorer survival. In an interview at the San Antonio Breast Cancer Symposium, Dr. Sarat Chandarlapaty of Memorial Sloan Kettering Cancer Center, New York, discusses a mutational analysis of cell-free DNA in blood samples from the BOLERO-2 trial and how the findings may help refine therapeutic strategies.